vs
InvenTrust Properties Corp.（IVT）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是InvenTrust Properties Corp.的1.6倍（$127.1M vs $77.4M），再鼎医药同比增速更快（17.1% vs 8.6%），InvenTrust Properties Corp.自由现金流更多（$110.9M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 7.6%）
InvenTrust Properties Corp.是一家专注于购物中心投资的房地产投资信托基金，截至2024年12月31日，公司共持有68处物业的权益，总建筑面积达1100万平方英尺，在商业地产投资领域拥有成熟的运营布局与资产储备。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
IVT vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.6倍
$77.4M
营收增速更快
ZLAB
高出8.5%
8.6%
自由现金流更多
IVT
多$137.6M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
7.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.4M | $127.1M |
| 净利润 | $2.7M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | -11.0% | -54.6% |
| 净利率 | 3.4% | — |
| 营收同比 | 8.6% | 17.1% |
| 净利润同比 | -72.8% | — |
| 每股收益（稀释后） | $0.02 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IVTZLAB
| Q4 25 | $77.4M | $127.1M | ||
| Q3 25 | $74.5M | $115.4M | ||
| Q2 25 | $73.6M | $109.1M | ||
| Q1 25 | $73.8M | $105.7M | ||
| Q4 24 | $71.2M | $108.5M | ||
| Q3 24 | $68.5M | $101.8M | ||
| Q2 24 | $67.4M | $100.1M | ||
| Q1 24 | $66.8M | $87.1M |
净利润IVTZLAB
| Q4 25 | $2.7M | — | ||
| Q3 25 | $6.0M | $-36.0M | ||
| Q2 25 | $95.9M | $-40.7M | ||
| Q1 25 | $6.8M | $-48.4M | ||
| Q4 24 | $9.8M | — | ||
| Q3 24 | $-539.0K | $-41.7M | ||
| Q2 24 | $1.5M | $-80.3M | ||
| Q1 24 | $2.9M | $-53.5M |
毛利率IVTZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率IVTZLAB
| Q4 25 | -11.0% | -54.6% | ||
| Q3 25 | -9.8% | -42.3% | ||
| Q2 25 | — | -50.3% | ||
| Q1 25 | -10.5% | -53.3% | ||
| Q4 24 | -3.6% | -62.6% | ||
| Q3 24 | -18.7% | -66.6% | ||
| Q2 24 | -13.6% | -76.0% | ||
| Q1 24 | -13.1% | -80.7% |
净利率IVTZLAB
| Q4 25 | 3.4% | — | ||
| Q3 25 | 8.1% | -31.2% | ||
| Q2 25 | 130.4% | -37.3% | ||
| Q1 25 | 9.2% | -45.8% | ||
| Q4 24 | 13.8% | — | ||
| Q3 24 | -0.8% | -40.9% | ||
| Q2 24 | 2.2% | -80.2% | ||
| Q1 24 | 4.3% | -61.4% |
每股收益（稀释后）IVTZLAB
| Q4 25 | $0.02 | $-0.05 | ||
| Q3 25 | $0.08 | $-0.03 | ||
| Q2 25 | $1.23 | $-0.04 | ||
| Q1 25 | $0.09 | $-0.04 | ||
| Q4 24 | $0.14 | $-0.09 | ||
| Q3 24 | $-0.01 | $-0.04 | ||
| Q2 24 | $0.02 | $-0.08 | ||
| Q1 24 | $0.04 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $825.9M | — |
| 股东权益账面价值 | $1.8B | $715.5M |
| 总资产 | $2.8B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.46× | — |
8季度趋势，按日历期对齐
现金及短期投资IVTZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
总债务IVTZLAB
| Q4 25 | $825.9M | — | ||
| Q3 25 | $764.6M | — | ||
| Q2 25 | $746.3M | — | ||
| Q1 25 | $740.7M | — | ||
| Q4 24 | $740.4M | — | ||
| Q3 24 | $740.1M | — | ||
| Q2 24 | $812.2M | — | ||
| Q1 24 | $827.5M | — |
股东权益IVTZLAB
| Q4 25 | $1.8B | $715.5M | ||
| Q3 25 | $1.8B | $759.9M | ||
| Q2 25 | $1.8B | $791.7M | ||
| Q1 25 | $1.7B | $810.8M | ||
| Q4 24 | $1.8B | $840.9M | ||
| Q3 24 | $1.8B | $667.7M | ||
| Q2 24 | $1.5B | $704.2M | ||
| Q1 24 | $1.5B | $762.2M |
总资产IVTZLAB
| Q4 25 | $2.8B | $1.2B | ||
| Q3 25 | $2.7B | $1.2B | ||
| Q2 25 | $2.7B | $1.2B | ||
| Q1 25 | $2.6B | $1.2B | ||
| Q4 24 | $2.6B | $1.2B | ||
| Q3 24 | $2.6B | $985.3M | ||
| Q2 24 | $2.5B | $987.4M | ||
| Q1 24 | $2.5B | $988.4M |
负债/权益比IVTZLAB
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.42× | — | ||
| Q4 24 | 0.42× | — | ||
| Q3 24 | 0.42× | — | ||
| Q2 24 | 0.53× | — | ||
| Q1 24 | 0.53× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $155.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $110.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | 143.3% | -21.0% |
| 资本支出强度资本支出/营收 | 57.5% | 0.5% |
| 现金转化率经营现金流/净利润 | 58.41× | — |
| 过去12个月自由现金流最近4个季度 | $193.1M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流IVTZLAB
| Q4 25 | $155.4M | $-26.0M | ||
| Q3 25 | $43.8M | $-32.0M | ||
| Q2 25 | $48.7M | $-31.0M | ||
| Q1 25 | $20.2M | $-61.7M | ||
| Q4 24 | $136.9M | $-55.8M | ||
| Q3 24 | $38.4M | $-26.8M | ||
| Q2 24 | $46.7M | $-42.2M | ||
| Q1 24 | $14.8M | $-90.1M |
自由现金流IVTZLAB
| Q4 25 | $110.9M | $-26.7M | ||
| Q3 25 | $31.4M | $-35.0M | ||
| Q2 25 | $38.0M | $-33.9M | ||
| Q1 25 | $12.8M | $-63.2M | ||
| Q4 24 | $100.8M | $-58.4M | ||
| Q3 24 | $29.3M | $-28.2M | ||
| Q2 24 | $37.2M | $-42.9M | ||
| Q1 24 | $7.7M | $-91.1M |
自由现金流率IVTZLAB
| Q4 25 | 143.3% | -21.0% | ||
| Q3 25 | 42.2% | -30.4% | ||
| Q2 25 | 51.6% | -31.1% | ||
| Q1 25 | 17.4% | -59.9% | ||
| Q4 24 | 141.5% | -53.8% | ||
| Q3 24 | 42.8% | -27.7% | ||
| Q2 24 | 55.2% | -42.9% | ||
| Q1 24 | 11.5% | -104.5% |
资本支出强度IVTZLAB
| Q4 25 | 57.5% | 0.5% | ||
| Q3 25 | 16.7% | 2.6% | ||
| Q2 25 | 14.6% | 2.6% | ||
| Q1 25 | 10.0% | 1.5% | ||
| Q4 24 | 50.7% | 2.4% | ||
| Q3 24 | 13.3% | 1.3% | ||
| Q2 24 | 14.0% | 0.7% | ||
| Q1 24 | 10.6% | 1.1% |
现金转化率IVTZLAB
| Q4 25 | 58.41× | — | ||
| Q3 25 | 7.27× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 2.97× | — | ||
| Q4 24 | 13.97× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 31.15× | — | ||
| Q1 24 | 5.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IVT
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
